Adjuvant progestagens for endometrial cancer

Cochrane Database of Systematic Reviews

Volumn 2011, Issue 6, 2011, Pages

  Martin Hirsch, Pierre P L ^a   Bryant, Andrew ^b   Keep, Sarah L ^a   Kitchener, Henry C ^c   Lilford, Richard ^d  

^a ROYAL PRESTON HOSPITAL   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GESTAGEN; HYDROXYPROGESTERONE CAPROATE; MEDROXYPROGESTERONE ACETATE; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; PROGESTERONE DERIVATIVE;

ADVANCED CANCER; ALLERGY; ALOPECIA; ANEMIA; ANOREXIA; BLEEDING; CANCER INCIDENCE; CANCER PATIENT; CANCER RECURRENCE; CANCER STAGING; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DEVELOPED COUNTRY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; ENDOMETRIUM CANCER; FEMALE; GASTROINTESTINAL SYMPTOM; GENITAL TRACT CARCINOMA; HAZARD RATIO; HUMAN; HYPERTENSION; LEUKOPENIA; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROCTITIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RECURRENCE FREE SURVIVAL; REVIEW; RISK ASSESSMENT; RISK REDUCTION; STOMATITIS; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; THROMBOEMBOLISM; VOMITING; ADJUVANT CHEMOTHERAPY; CAUSE OF DEATH; ENDOMETRIUM TUMOR; META ANALYSIS; MORTALITY; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANTINEOPLASTIC AGENTS, HORMONAL; CAUSE OF DEATH; CHEMOTHERAPY, ADJUVANT; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; HYDROXYPROGESTERONES; MEDROXYPROGESTERONE ACETATE; PROGESTINS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 80052046641     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD001040.pub2     Document Type: Review

References (19)

1. COSA-NZ-UK Endometrial Cancer Groups. Adjuvant medroxyprogesterone acetate in high-risk endometrial cancer. International Journal of Gynecological Cancer 1998;8:387-91.
2. DePalo G, Mangioni C, Periti P, Del Vecchio M, Marubini E. Treatment of FIGO (1971) stage 1 endometrial carcinoma with intensive surgery, radiotherapy and hormonotherapy according to pathological prognostic groups. Long term results of a randomised multicentre trial. European Journal of Cancer 1993;29a:1133-40.
3. Lewis GC, Slack NH, Mortel R, Bross I. Adjuvant progestagen therapy in the definitive treatment of endometrial cancer. Gynecologic Oncology 1974;2:368-76.
4. MacDonald RR, Thorogood J, Mason MK. A randomised trial of progestagens in the primary treatment of endometrial carcinoma. British Journal of Obstetrics and Gynaecology 1988;95:166-74.
5. Malkasian G, Decker D. Aduvant progesterone therapy for stage 1 endometrial cancer. International Journal of Gynaecology and Obstetrics 1978;16:48-9.
6. Urbanski K, Karolewski K, Kojs Z, Klimek M, Dyba T. Adjuvant progestagen therapy improves survival in patients with endometrial cancer after hysterectomy. results of one-institutional prospective clinical trial. European Journal of Gynaecologic Oncology 1993;14 suppl:98-104.
7. Vergote I, Kjorstad K, Abeler V, Kolstad P. A randomised trial of adjuvant progestagens in early endometrial cancer. Cancer 1989;64:1011-6.
8. Baekelandt MM, Castiglione M, on behalf of the ESMO Guidelines Working Group. Endometrial carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up [Endometrial carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up]. Annals of Oncology. 2009;20(supplement 4):29-31.
9. Uterus (womb) cancer - UK incidence statistics. http://info.cancerresearchuk.org/cancerstats/types/uterus/incidence/index.htm. 2010.
10. CTCAE. Common Terminology Criteria for Adverse Events. (http://ctep.cancer.gov/forms/CTCAEv3.pdf) 9th August 2006; Vol. v3.0 (CTCAE).
11. Deeks JJ, Altman DG, Bradburn MJ. Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. In: Egger M, Davey Smith G, Altman DG (eds). Systematic Reviews in Health Care: Meta-Analysis in Context (2nd edition). London: BMJ Publication Group, 2001.
12. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-188.
13. Sant M, Aareleid T, Berrino F, Bielska Lasota M, Carli PM, Faivre J, Grosclaude P, Hédelin G, Matsuda T, Møller H, Möller T, Verdecchia A, Capocaccia R, Gatta G, Micheli A, Santaquilani M, Roazzi P, Lisi D, and the EUROCARE Working Group. EUROCARE-3: survival of cancer patients diagnosed 1990-94-results and commentary. Annals of Oncology 2003;14 (Supplement 5):v61-v118.
14. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002. Cancer Incidence, Mortality and Prevalence Worldwide. IARC CancerBase No. 5, version 2.0. IARCPress, Lyon 2004.
15. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-560.
16. Kauppila A. Progestin therapy of endometrial, breast and ovarian carcinoma. A review of clinical observations. Acta Obstet Gynecol Scand. 1984;63(5):441-50.
17. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine 1998;17(24):2815-34.
18. Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. International Journal of Gynecology and Obstetrics 2009;105(2):103-4.
19. Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Waldron W, et al. Surveillance Epidemiology and End Results Cancer Statistics Review, 1975-2008. National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2008/, based on November 2010 SEER data submission, posted to the SEER web site, 2011.